Neuroone Total Current Liabilities vs Depreciation And Amortization Analysis
NMTC Stock | USD 0.62 0.08 11.43% |
Neuroone Medical financial indicator trend analysis is infinitely more than just investigating Neuroone Medical Tec recent accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Neuroone Medical Tec is a good investment. Please check the relationship between Neuroone Medical Total Current Liabilities and its Depreciation And Amortization accounts. Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Neuroone Medical Technologies. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in estimate.
Total Current Liabilities vs Depreciation And Amortization
Total Current Liabilities vs Depreciation And Amortization Correlation Analysis
The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Neuroone Medical Tec Total Current Liabilities account and Depreciation And Amortization. At this time, the significance of the direction appears to have fragmental relationship.
The correlation between Neuroone Medical's Total Current Liabilities and Depreciation And Amortization is 0.48. Overlapping area represents the amount of variation of Total Current Liabilities that can explain the historical movement of Depreciation And Amortization in the same time period over historical financial statements of Neuroone Medical Technologies, assuming nothing else is changed. The correlation between historical values of Neuroone Medical's Total Current Liabilities and Depreciation And Amortization is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Total Current Liabilities of Neuroone Medical Technologies are associated (or correlated) with its Depreciation And Amortization. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Depreciation And Amortization has no effect on the direction of Total Current Liabilities i.e., Neuroone Medical's Total Current Liabilities and Depreciation And Amortization go up and down completely randomly.
Correlation Coefficient | 0.48 |
Relationship Direction | Positive |
Relationship Strength | Weak |
Total Current Liabilities
Total Current Liabilities is an item on Neuroone Medical balance sheet that include short term debt, accounts payable, accrued salaries payable, payroll taxes payable, accrued liabilities and other debts. Total Current Liabilities of Neuroone Medical Technologies are important to investors because some useful performance ratios such as Current Ratio and Quick Ratio require Total Current Liabilities to be accurate. The total amount of liabilities that a company is expected to pay within one year, including debts, accounts payable, and other short-term financial obligations.Depreciation And Amortization
The systematic reduction in the recorded value of an intangible asset. This includes the allocation of the cost of tangible assets to periods in which the assets are used, representing the expense related to the wear and tear, deterioration, or obsolescence of physical assets and intangible assets over their useful lives.Most indicators from Neuroone Medical's fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Neuroone Medical Tec current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Neuroone Medical Technologies. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in estimate. At present, Neuroone Medical's Sales General And Administrative To Revenue is projected to increase significantly based on the last few years of reporting.
Neuroone Medical fundamental ratios Correlations
Click cells to compare fundamentals
Neuroone Medical Account Relationship Matchups
High Positive Relationship
High Negative Relationship
Neuroone Medical fundamental ratios Accounts
2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
Common Stock Shares Outstanding | 5.4M | 10.7M | 16.0M | 18.1M | 20.8M | 21.9M | |
Total Assets | 4.8M | 7.9M | 12.8M | 8.1M | 9.3M | 9.8M | |
Other Current Liab | 454.9K | 531.5K | 632.5K | 978.4K | 1.1M | 1.2M | |
Total Current Liabilities | 2.4M | 1.2M | 3.1M | 1.8M | 2.1M | 1.2M | |
Total Stockholder Equity | 2.1M | 6.6M | 9.6M | 6.2M | 7.2M | 7.5M | |
Net Debt | (2.7M) | (6.6M) | (8.0M) | (5.1M) | (4.6M) | (4.4M) | |
Retained Earnings | (30.9M) | (40.8M) | (50.8M) | (62.7M) | (56.4M) | (53.6M) | |
Cash | 4.0M | 6.9M | 8.2M | 5.3M | 6.1M | 6.4M | |
Cash And Short Term Investments | 4.0M | 6.9M | 11.1M | 5.3M | 6.1M | 6.4M | |
Liabilities And Stockholders Equity | 4.8M | 7.9M | 12.8M | 8.1M | 9.3M | 9.8M | |
Non Current Liabilities Total | 337.7K | 202.9K | 119.6K | 55.3K | 63.6K | 60.4K | |
Total Liab | 2.7M | 1.4M | 3.2M | 1.8M | 2.1M | 1.4M | |
Total Current Assets | 4.2M | 7.3M | 12.2M | 7.3M | 8.4M | 8.8M | |
Common Stock | 22.2K | 12.0K | 16.2K | 23.9K | 27.5K | 28.9K | |
Other Stockholder Equity | 32.9M | 47.4M | 60.4M | 68.9M | 79.2M | 83.2M | |
Accounts Payable | 762.5K | 528.8K | 927.7K | 685.1K | 787.9K | 475.4K | |
Net Tangible Assets | (1.4M) | 1.9M | 6.4M | 9.5M | 10.9M | 11.5M | |
Non Current Assets Total | 604.8K | 646.5K | 646.8K | 784.4K | 902.0K | 947.2K | |
Non Currrent Assets Other | 200.1K | 230.9K | 156.5K | (784.4K) | (706.0K) | (670.7K) | |
Other Current Assets | 118.6K | 244.0K | 296.6K | 263.7K | 303.3K | 318.5K | |
Intangible Assets | 156.5K | 134.2K | 111.9K | 89.6K | 80.6K | 120.0K | |
Property Plant Equipment | 52.0K | 448.2K | 512.3K | 535.0K | 615.2K | 646.0K | |
Net Invested Capital | 3.1M | 6.6M | 9.6M | 6.2M | 7.2M | 7.5M | |
Net Working Capital | 1.8M | 6.1M | 9.1M | 5.5M | 6.3M | 6.7M | |
Capital Stock | 22.2K | 35.8K | 16.2K | 23.9K | 27.5K | 22.2K | |
Property Plant And Equipment Net | 448.2K | 512.3K | 535.0K | 694.8K | 799.0K | 493.3K |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether Neuroone Medical Tec offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Neuroone Medical's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Neuroone Medical Technologies Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Neuroone Medical Technologies Stock:Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Neuroone Medical Technologies. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in estimate. You can also try the Equity Analysis module to research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities.
Is Health Care Equipment & Supplies space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Neuroone Medical. If investors know Neuroone will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Neuroone Medical listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (0.48) | Revenue Per Share 0.158 | Quarterly Revenue Growth 0.311 | Return On Assets (1.43) | Return On Equity (3.49) |
The market value of Neuroone Medical Tec is measured differently than its book value, which is the value of Neuroone that is recorded on the company's balance sheet. Investors also form their own opinion of Neuroone Medical's value that differs from its market value or its book value, called intrinsic value, which is Neuroone Medical's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Neuroone Medical's market value can be influenced by many factors that don't directly affect Neuroone Medical's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Neuroone Medical's value and its price as these two are different measures arrived at by different means. Investors typically determine if Neuroone Medical is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Neuroone Medical's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.